CFF provided the following clinical trial update on 12/15/2016:
Description: This was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (OrkambiĀ®). This study was for younger children with CF who have two copies of the F508del CFTR mutation.
Age: 6 Years to 11 Years
Mutation: Two Copies F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 11
Length of Participation: 27 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/show/NCT01897233